Comparison of QT interval prolongation incidence in cardiology intensive care unit patients treated with moxifloxacin versus levofloxacin and analysis of related risk factors
10.3760/cma.j.cn114015-20240410-00241
- VernacularTitle:莫西沙星与左氧氟沙星在心脏重症监护病房患者中QT间期延长发生率的比较及相关危险因素分析
- Author:
Chao WEN
1
;
Xiaoxia TANG
;
Jinfeng ZHANG
;
Man DUAN
;
Gang CHEN
;
Wenwen ZHU
;
Ya WANG
Author Information
1. 孝感市中心医院药学部，孝感 432000
- Publication Type:Journal Article
- Keywords:
Quinolones;
Moxifloxacin;
Levofloxacin;
Long QT syndrome;
Risk factors
- From:
Adverse Drug Reactions Journal
2024;26(7):412-416
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the differences in the incidence of QT interval prolongation between moxifloxacin and levofloxacin in anti-infective therapy among cardiology intensive care unit (CCU) patients, and to analyze the risk factors for QT interval prolongation.Methods:The data of patients who received anti-infective treatments with moxifloxacin and levofloxacin in CCU of Xiaogan Central Hospital from January 2020 to December 2022 were collected and analyzed retrospectively. The clinical characteristics in the 2 groups were compared. Potential influencing factors of QT interval prolongation were analyzed using univariate regression analysis. Variables with P<0.2 were included in a logistic regression model for multivariate analysis. The effect values were expressed as odds ratio ( OR) and its 95% confidence interval ( CI). Results:A total of 146 patients were included in the study, with 76 patients in the moxifloxacin group and 70 patients in the levofloxacin group. In the moxifloxacin group, 18 out of 76 patients (23.68%) experienced QT interval prolongation, while in the levofloxacin group, 6 out of 70 patients (8.57%) experienced QT interval prolongation; the difference between the 2 groups was statistically significant ( P=0.025). There were no statistically significant differences in other factors between the 2 groups. Univariate regression analysis showed that female ( OR=2.958, 95% CI: 1.144-7.647, P=0.025), myocardial infarction ( OR=2.958, 95% CI: 1.144-7.647, P=0.025), concomitant use of amiodarone ( OR=2.569, 95% CI: 1.042-6.337, P=0.040) and escitalopram were influencing factors of QT interval prolongation. Factors with P<0.2 were entered in the multivariate logistic regression analysis, and the results showed that female ( OR=3.616, 95% CI: 1.240-10.538, P=0.019), hypokalemia ( OR=2.953, 95% CI: 1.263-6.905, P=0.012), and myocardial infarction ( OR=3.026, 95% CI: 1.057-8.666, P=0.039) were independent risk factors for QT interval prolongation. Conclusions:Moxifloxacin is associated with a higher incidence of QT interval prolongation compared to levofloxacin. Female and patients with hypokalemia and myocardial infarction have high risks for QT interval prolongation.
